A new chapter opens at privately-held Italian drugmaker Chiesi Farmaceutici as the 11-year tenure of chief executive Ugo Di Francesco, aged 62, comes to a close at the end of 2022. 5 September 2022
Private equity firm Permira, in partnership with the Marcucci family and supported by their co-investors, have completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL). 1 September 2022
Ocugen, a US biotech focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, has announced the appointment of Robert Hopkins as chief medical officer (CMO) and Arun Upadhyay as chief scientific officer (CSO). 1 September 2022
Scandion Oncology, a Danish biotech developing medicines for treatment-resistant cancer, has announced that president and chief executive Bo Rode Hansen will leave his position with immediate effect by mutual agreement. 31 August 2022
Celsius Therapeutics, a privately-held biotech developing precision medicines for cancer and autoimmune disease through single-cell RNA sequencing, has named Sarah Grant its chief medical officer (CMO). 26 August 2022
As had long been expected, Novartis has announced plans to hive off its generics business, Sandoz, creating a new publicly-traded company. 25 August 2022
AstriVax, a start-up working to develop novel vaccines, has raised the largest amount of seed capital in the history of Belgium-based university KU Leuven spin-offs, totalling $30 million. 25 August 2022
British biotech Mereo BioPharma has revealed its largest shareholder is agitating to purge certain board members as part of a plan to change the firm’s strategic direction. 23 August 2022
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, today announced the appointment of Thomas Willemsen as its president and chief executive, effective October 1, 2022. 22 August 2022
Privately-held North Carolina, USA-based contract research organization BioAgilytix has named Linda Robbie its new chief operating officer. 17 August 2022
PsiOxus, a clinical-stage biotechnology company developing a novel platform technology for the targeted delivery of therapeutic transgenes to solid tumors, has announced the appointment of its new chief executive, Howard Davis. 12 August 2022
California, USA-based Appia Bio, a pre-clinical-stage biotechnology company today announced that Jason Damiano has been appointed as its chief scientific officer. 10 August 2022
Privately-held Danish dermatology specialist LEO Pharma has announced the appointment of Sven Hauptmann as its new executive vice president of global product supply. 4 August 2022
The Johnson & Johnson subsidiary Janssen UK has named Maria Walsh its business unit director, oncology and hematology, cell and gene therapy and pulmonary hypertension. 27 July 2022
Netherlands-based specialty pharma firm Pleco Therapeutics today announced its expansion, with the incorporation if a US subsidiary, Pleco Therapeutics USA. 26 July 2022
US discoverer of precision medicines for cancer and other diseases, Flare Therapeutics, today announced the appointment of Amit Rakhit as president and chief executive. 25 July 2022
Swiss drugmaker Roche announced its financial results for the first half of 2022 on Thursday, as well as revealing that chief executive Severin Schwan will step down next March after 15 years in the top job. 21 July 2022
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024